Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.

about

Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US.

Item

http://www.wikidata.org/entity/Q52820899

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@en

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@nl

type

Item

label

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@en

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@nl

prefLabel

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@en

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@nl

P1476

Incidence of type 2 diabetes m ...... yelogenous leukemia in the US.

@en

P2093

Deepak Yerragolam

http://www.w3.org/2001/XMLSchema#string

Dinara Makenbaeva

http://www.w3.org/2001/XMLSchema#string

Leah Burns

http://www.w3.org/2001/XMLSchema#string

Meg Franklin

http://www.w3.org/2001/XMLSchema#string

Samuel Perez

http://www.w3.org/2001/XMLSchema#string

P2860

Overriding imatinib resistance with a novel ABL kinase inhibitor

Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity

Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.

How tyrosine kinase inhibitors impair metabolism and endocrine system function: a systematic updated review.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

P304

353-360

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03007995.2017.1399870

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29095654

http://www.w3.org/2001/XMLSchema#string

P921

hyperlipidemia

type-2 diabetes